Skip to content
Back to News & Insights
Company News15 October 2026

Object Pharma Strengthens Its European Presence Through ObNowa Pharma

Object Pharma Strengthens Its European Presence Through ObNowa Pharma

Object Pharma's ecosystem in Europe continues to develop through ObNowa Pharma, a pharmaceutical development company headquartered in Warsaw, Poland, focused on medical aesthetics.

ObNowa Pharma's activities include European clinical development, regulatory strategy and commercialization. Its portfolio brings together neurotoxin-based aesthetic opportunities — including a bio-comparable program designed around established performance standards and a bio-better program exploring differentiated characteristics — alongside licensed hair and eyebrow programs in clinical development.

Maksymilian Świniarski has been appointed President of ObNowa Pharma. He brings extensive international pharmaceutical leadership experience to the role, with responsibilities spanning business development, partnerships, fundraising and commercial strategy.

From its base in Warsaw — inside the European Union's single regulatory and commercial space — ObNowa Pharma develops its programs to global and EU regulatory standards. The establishment of ObNowa Pharma expanded Object Pharma's ecosystem into European pharmaceutical development and medical aesthetics, complementing Object Pharma's central commitment to neurotoxin science for mental and brain health.

More information about ObNowa Pharma is available on the company's official website.